TY - JOUR
T1 - Clinical characteristics of patients with not well-controlled severe asthma in Japan
T2 - Analysis of the Keio Severe Asthma Research Program in Japanese population (KEIO-SARP) registry
AU - Tanosaki, Takae
AU - Kabata, Hiroki
AU - Matsusaka, Masako
AU - Miyata, Jun
AU - Masaki, Katsunori
AU - Mochimaru, Takao
AU - Okuzumi, Shinichi
AU - Kuwae, Misato
AU - Watanabe, Risa
AU - Suzuki, Yusuke
AU - Sayama, Koichi
AU - Izuhara, Kenji
AU - Asano, Koichiro
AU - Fukunaga, Koichi
N1 - Funding Information:
This study was supported in part by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science , a research grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development , and a grant-in-aid from GlaxoSmithKline PLC. . None of these supporting organizations were involved in the study design; collection, analysis, and interpretation of data; or writing of the report in this study. Data extraction and statistical analyses were performed by Linical Co., Ltd. and funded by AstraZeneca K.K. Medical writing support was provided by Mami Hirano, MS, of Cactus Communications and funded by AstraZeneca K.K.
Funding Information:
JM received a research grant from GSK Japan. KI received research funding from Shino-Test. KA received honoraria from Astellas Pharma, Boehringer Ingelheim, Kyorin Pharmaceutical, MSD, Novartis Pharma, and AstraZeneca. KF received honoraria from Boehringer Ingelheim and AstraZeneca. The rest of the authors have no conflict of interest.
Funding Information:
We thank all the members of the KEIO-SARP study, Chiyomi Uemura, and Junya Ono for their assistance. We also thank our late professor, Tomoko Betsuyaku, for her great contributions to the KEIO-SARP study. This study was supported in part by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science, a research grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development, and a grant-in-aid from GlaxoSmithKline PLC. None of these supporting organizations were involved in the study design; collection, analysis, and interpretation of data; or writing of the report in this study. Data extraction and statistical analyses were performed by Linical Co. Ltd. and funded by AstraZeneca K.K. Medical writing support was provided by Mami Hirano, MS, of Cactus Communications and funded by AstraZeneca K.K.
Publisher Copyright:
© 2020 Japanese Society of Allergology
PY - 2021/1
Y1 - 2021/1
N2 - Background: Multiple phenotypes exist within the classification of severe asthma. However, characteristics of patients with not well-controlled severe asthma have not been well identified. Methods: Japanese patients with asthma (age ≥ 20 years) were enrolled at the Keio University Hospital and its affiliated hospitals in this observational study (Keio Severe Asthma Research Program). Among them, patients with severe asthma (those undergoing Global Initiative for Asthma [GINA] 2018 step 4 or 5 treatment) were included in this analysis and investigated clinical characteristics based on asthma control status. Results: Of the 154 patients (men, 46.8%; age, 60.1 ± 14.9 years), 87 (56.5%) had not well-controlled (partly controlled and uncontrolled) asthma (GINA step 4, 42 patients; step 5, 45 patients). Overall, there were no significant differences in clinical characteristics between patients with well-controlled and not well-controlled asthma. However, cluster analysis revealed that distinct 5 clusters (cluster 1, well-controlled; cluster 2, eosinophilic; cluster 3, non–type 2 inflammation; cluster 4, high periostin; and cluster 5, late-onset type 2 inflammation), and clusters 2–5 were not well-controlled. Among them, cluster 3 was characterized by low eosinophil counts, low periostin levels, and less frequent olfactory disturbance, and this cluster had the worst asthma control. Conclusions: Japanese patients with severe asthma were divided into well-controlled and not-well controlled asthma, and we confirmed heterogeneity of not well-controlled severe asthma. These patients, especially non-type 2 phenotype, require a further therapeutic approach. (University Hospital Medical Information Network Clinical Trials Registry, UMIN000002980)
AB - Background: Multiple phenotypes exist within the classification of severe asthma. However, characteristics of patients with not well-controlled severe asthma have not been well identified. Methods: Japanese patients with asthma (age ≥ 20 years) were enrolled at the Keio University Hospital and its affiliated hospitals in this observational study (Keio Severe Asthma Research Program). Among them, patients with severe asthma (those undergoing Global Initiative for Asthma [GINA] 2018 step 4 or 5 treatment) were included in this analysis and investigated clinical characteristics based on asthma control status. Results: Of the 154 patients (men, 46.8%; age, 60.1 ± 14.9 years), 87 (56.5%) had not well-controlled (partly controlled and uncontrolled) asthma (GINA step 4, 42 patients; step 5, 45 patients). Overall, there were no significant differences in clinical characteristics between patients with well-controlled and not well-controlled asthma. However, cluster analysis revealed that distinct 5 clusters (cluster 1, well-controlled; cluster 2, eosinophilic; cluster 3, non–type 2 inflammation; cluster 4, high periostin; and cluster 5, late-onset type 2 inflammation), and clusters 2–5 were not well-controlled. Among them, cluster 3 was characterized by low eosinophil counts, low periostin levels, and less frequent olfactory disturbance, and this cluster had the worst asthma control. Conclusions: Japanese patients with severe asthma were divided into well-controlled and not-well controlled asthma, and we confirmed heterogeneity of not well-controlled severe asthma. These patients, especially non-type 2 phenotype, require a further therapeutic approach. (University Hospital Medical Information Network Clinical Trials Registry, UMIN000002980)
KW - Asthma
KW - Biomarkers
KW - Molecular targeted therapy
KW - Observational study
KW - Symptom assessment
UR - http://www.scopus.com/inward/record.url?scp=85087709489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087709489&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2020.06.002
DO - 10.1016/j.alit.2020.06.002
M3 - Article
C2 - 32651123
AN - SCOPUS:85087709489
SN - 1323-8930
VL - 70
SP - 61
EP - 67
JO - Allergology International
JF - Allergology International
IS - 1
ER -